Cargando…

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miura, Koh, Kinouchi, Makoto, Ishida, Kazuyuki, Fujibuchi, Wataru, Naitoh, Takeshi, Ogawa, Hitoshi, Ando, Toshinori, Yazaki, Nobuki, Watanabe, Kazuhiro, Haneda, Sho, Shibata, Chikashi, Sasaki, Iwao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837334/ https://www.ncbi.nlm.nih.gov/pubmed/24281184 http://dx.doi.org/10.3390/cancers2031717

Ejemplares similares

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
por: Fleming, R. A., et al.
Publicado: (1992)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020)

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment
por: Anaka, Matthew, et al.
Publicado: (2022)

Whole transcriptome sequence data of 5-FU sensitive and 5-FU resistant tumors generated in a mouse model of de novo carcinogenesis
por: Iacovides, Demetris, et al.
Publicado: (2018)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2012)

5-FU-induced cardiac toxicity - an underestimated problem in radiooncology?
por: Steger, Felix, et al.
Publicado: (2012)

The role of GLI1 for 5-Fu resistance in colorectal cancer
por: Zhang, Lining, et al.
Publicado: (2017)

5-FU induced cardiotoxicity: case series and review of the literature
por: Yuan, Cai, et al.
Publicado: (2019)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
por: Sadighi, Sanambar, et al.
Publicado: (2006)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
por: Schlumberger, M., et al.
Publicado: (1995)

γ-tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2
por: TAKANO, HIDEYUKI, et al.
Publicado: (2015)

EPEN-30. 5FU with Radiation Followed by Maintenance of 5FU and ATRA Significantly Improves Survival of 1q+/6q- PFA Ependymoma Xenograft Models
por: Grimaldo, Enrique, et al.
Publicado: (2022)

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU
por: TANG, BO, et al.
Publicado: (2016)

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU
por: Tang, Bo, et al.
Publicado: (2018)

Protective effect of dexamethasone on 5-FU-induced oral mucositis in hamsters
por: Ribeiro, Susana Barbosa, et al.
Publicado: (2017)

Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer
por: Zhu, Yiping, et al.
Publicado: (2020)

Thermosensitive Interfacial Migration of 5-FU in the Microenvironment of Pluronic Block Copolymers
por: Lin, Tz-Feng, et al.
Publicado: (2021)

Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma
por: Öman, Mikael, et al.
Publicado: (2021)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

Transcriptomic and network pharmacology approaches revealed possible mechanisms underlying the 5-fluorouracil (5-FU)-sensitizing effect of Xuan-Fu-Hua decoction treatment on liver cancer cells
por: Luo, Wen-Zhao, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1988)

[Retracted] Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU
por: Tang, Bo, et al.
Publicado: (2023)

The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2018)

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports
por: Brickell, K, et al.
Publicado: (2003)

5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice
por: Wang, Yongsheng, et al.
Publicado: (2010)

Knockout of SIRT4 decreases chemosensitivity to 5-FU in colorectal cancer cells
por: Zhu, Yuanyuan, et al.
Publicado: (2018)

Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells
por: He, Lingfeng, et al.
Publicado: (2018)

Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients
por: Fang, Ling, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2s7q2i25hms87bqo4sm6umqt4q